Hunan Er-Kang Pharmaceutical Co., Ltd (SHE:300267)
China flag China · Delayed Price · Currency is CNY
2.830
-0.090 (-3.08%)
Nov 13, 2026, 3:04 PM CST

SHE:300267 Balance Sheet

Millions CNY. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Cash & Equivalents
960897.4698.54744.35764.67761.56
Trading Asset Securities
-901200.12114.12-
Cash & Short-Term Investments
960987.4818.54744.47878.79761.56
Cash Growth
20.12%20.63%9.95%-15.28%15.39%-40.90%
Accounts Receivable
174.4202.39198.3177.8204.48274.36
Other Receivables
2.683.624.4618.1727.8113.57
Receivables
177.08206.02202.77195.97232.29287.93
Inventory
694.62512600.78691.6821.34714.77
Prepaid Expenses
---1.39--
Other Current Assets
130.7883.159597.58158.78182.1
Total Current Assets
1,9621,7891,7171,7312,0911,946
Property, Plant & Equipment
2,3672,4252,7162,9172,8572,604
Long-Term Investments
99.6899.8121.74170.23188.97196.16
Goodwill
222210.0110.01
Other Intangible Assets
303.32317.12363.56378.03406.14431.45
Long-Term Deferred Tax Assets
108.64120.4150.55152.14168.92118.34
Long-Term Deferred Charges
8.589.5610.6612.0819.516.51
Other Long-Term Assets
190.8798.25117.78116.25114.6108.75
Total Assets
5,0424,8615,2005,4795,8565,432

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Accounts Payable
122.27121.07114.66122.3198.7137.87
Accrued Expenses
12.4933.0226.0931.2223.3833.79
Short-Term Debt
669.17551.38488.2341.89396.64246
Current Portion of Leases
-8.793.692.164.113.88
Current Income Taxes Payable
3.940.020.170.990.970.74
Current Unearned Revenue
77.3626.1729.8247.0151.3137.35
Other Current Liabilities
60.4362.2742.7157.7350.3339.3
Total Current Liabilities
953.59802.73705.34603.3725.43498.93
Long-Term Leases
25.327.8617.381.172.582.15
Long-Term Unearned Revenue
7.7910.0614.9318.3923.1527.91
Long-Term Deferred Tax Liabilities
44.946.3246.946.253.4129.29
Other Long-Term Liabilities
--12.99---
Total Liabilities
1,032886.97797.54669.05804.57558.28

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Common Stock
2,0632,0632,0632,0632,0632,063
Additional Paid-In Capital
1,0191,0191,0191,0191,005998.96
Retained Earnings
996.54924.271,3041,6771,9351,889
Comprehensive Income & Other
5.7927.9561.2776.5248.34-99.15
Total Common Equity
4,0844,0344,4474,8365,0514,851
Minority Interest
-73.86-60.24-45.23-26.030.2722.49
Shareholders' Equity
4,0113,9744,4024,8105,0514,874
Total Liabilities & Equity
5,0424,8615,2005,4795,8565,432

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Total Debt
702.4588.03509.27345.21403.33252.04
Net Cash (Debt)
257.6399.38309.27399.25475.46509.53
Net Cash Growth
-7.55%29.13%-22.54%-16.03%-6.69%-38.28%
Net Cash Per Share
0.120.190.150.190.230.25
Filing Date Shares Outstanding
2,0732,0632,0632,0632,0632,063
Total Common Shares Outstanding
2,0732,0632,0632,0632,0632,063
Working Capital
1,009985.841,0121,1281,3661,447
Book Value Per Share
1.971.962.162.342.452.35
Tangible Book Value
3,7793,7154,0824,4564,6354,410
Tangible Book Value Per Share
1.821.801.982.162.252.14
Buildings
-1,8971,9331,9901,9261,740
Machinery
-1,7341,9141,8781,8961,224
Construction In Progress
-212.28174.58220.8952.92506.18